Singapore markets close in 5 hours 36 minutes
Straits Times Index
3,341.93 -6.94 (-0.21%) Nikkei
38,749.25 -173.78 (-0.45%) Hang Seng
18,500.58 +97.54 (+0.53%) FTSE 100
8,262.75 -12.63 (-0.15%) Bitcoin USD
69,239.17 +955.60 (+1.40%) CMC Crypto 200
1,450.06 -17.88 (-1.22%)
Eyenovia, Inc. (EYEN)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.8080 |
| Open | 0.8100 |
| Bid | 0.7504 x 100 |
| Ask | 0.7702 x 200 |
| Day's range | 0.7308 - 0.8100 |
| 52-week range | 0.5010 - 2.9800 |
| Volume | |
| Avg. volume | 1,307,512 |
| Market cap | 40.963M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7400 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
ZacksAll You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Eyenovia (EYEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GuruFocus.com
Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...
Despite a net loss, Eyenovia progresses with FDA approvals and strategic commercial expansions.
GlobeNewswireEyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery Company to host conference call and webcast today, May 15th, at 4:30 pm ET NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ
© 2024 Yahoo. All rights reserved.